Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review
Background: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-gener...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.964606/full |
| _version_ | 1811215018569498624 |
|---|---|
| author | Xiao Zhang Huan Han Jiuzhou Zhao Xiao Liu Jianbo Zhang Rui Sun Shaomei Li Baoxing Liu Hui Zhu Shuyue Jiao Xiang Li Hong Tang |
| author_facet | Xiao Zhang Huan Han Jiuzhou Zhao Xiao Liu Jianbo Zhang Rui Sun Shaomei Li Baoxing Liu Hui Zhu Shuyue Jiao Xiang Li Hong Tang |
| author_sort | Xiao Zhang |
| collection | DOAJ |
| description | Background: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-generation EGFR-TKIs has not been determined. Although emerging targeted therapies for EGFR exon 20 insertion mutation have been reported in recent years, such patients still have a poorer prognosis than those with typical or wild-type EGFR mutations.Case summary: Here, we report the case of a 57-year-old man with advanced non-small cell lung cancer (NSCLC) with a rare EGFR exon 20 N771_P772insH mutation. The patient was treated with furmonertinib as second-line therapy. Although his pleural effusion was more than before that during treatment, various examination results showed that the pleural effusion was closely related to hypoproteinemia; thus, local progression was not considered. His cough was significantly alleviated, and the dose was well tolerated. The patient was evaluated for a remarkable progression-free survival (PFS) of 10.0 months, a duration of response (DOR) of 8.0 months, and an overall survival (OS) of 22.0 months, which had not previously been achieved.Conclusion: The present study indicated that furmonertinib might be a good treatment option for first-line progressive NSCLC patients with EGFR exon 20 insertion mutation. |
| first_indexed | 2024-04-12T06:15:14Z |
| format | Article |
| id | doaj.art-c188ab216c774b0caa8b0ac264ecb5e5 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T06:15:14Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c188ab216c774b0caa8b0ac264ecb5e52022-12-22T03:44:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.964606964606Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature reviewXiao Zhang0Huan Han1Jiuzhou Zhao2Xiao Liu3Jianbo Zhang4Rui Sun5Shaomei Li6Baoxing Liu7Hui Zhu8Shuyue Jiao9Xiang Li10Hong Tang11Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaBackground: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-generation EGFR-TKIs has not been determined. Although emerging targeted therapies for EGFR exon 20 insertion mutation have been reported in recent years, such patients still have a poorer prognosis than those with typical or wild-type EGFR mutations.Case summary: Here, we report the case of a 57-year-old man with advanced non-small cell lung cancer (NSCLC) with a rare EGFR exon 20 N771_P772insH mutation. The patient was treated with furmonertinib as second-line therapy. Although his pleural effusion was more than before that during treatment, various examination results showed that the pleural effusion was closely related to hypoproteinemia; thus, local progression was not considered. His cough was significantly alleviated, and the dose was well tolerated. The patient was evaluated for a remarkable progression-free survival (PFS) of 10.0 months, a duration of response (DOR) of 8.0 months, and an overall survival (OS) of 22.0 months, which had not previously been achieved.Conclusion: The present study indicated that furmonertinib might be a good treatment option for first-line progressive NSCLC patients with EGFR exon 20 insertion mutation.https://www.frontiersin.org/articles/10.3389/fphar.2022.964606/fullNSCLCEGFR exon 20 insertion mutationN771_P772insHfurmonertinibsecond-line |
| spellingShingle | Xiao Zhang Huan Han Jiuzhou Zhao Xiao Liu Jianbo Zhang Rui Sun Shaomei Li Baoxing Liu Hui Zhu Shuyue Jiao Xiang Li Hong Tang Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review Frontiers in Pharmacology NSCLC EGFR exon 20 insertion mutation N771_P772insH furmonertinib second-line |
| title | Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review |
| title_full | Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review |
| title_fullStr | Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review |
| title_full_unstemmed | Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review |
| title_short | Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review |
| title_sort | case report a good response to furmonertinib second line treatment of an advanced lung adenocarcinoma patient with a rare egfr exon 20 n771 p772insh mutation a case report and literature review |
| topic | NSCLC EGFR exon 20 insertion mutation N771_P772insH furmonertinib second-line |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.964606/full |
| work_keys_str_mv | AT xiaozhang casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT huanhan casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT jiuzhouzhao casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT xiaoliu casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT jianbozhang casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT ruisun casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT shaomeili casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT baoxingliu casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT huizhu casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT shuyuejiao casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT xiangli casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview AT hongtang casereportagoodresponsetofurmonertinibsecondlinetreatmentofanadvancedlungadenocarcinomapatientwitharareegfrexon20n771p772inshmutationacasereportandliteraturereview |